Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
<h4>Background</h4>Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0119629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331853955170304 |
|---|---|
| author | Patricia J Munseri Arne Kroidl Charlotta Nilsson Agricola Joachim Christof Geldmacher Philipp Mann Candida Moshiro Said Aboud Eligius Lyamuya Leonard Maboko Marco Missanga Bahati Kaluwa Sayoki Mfinanga Lilly Podola Asli Bauer Karina Godoy-Ramirez Mary Marovich Bernard Moss Michael Hoelscher Frances Gotch Wolfgang Stöhr Richard Stout Sheena McCormack Britta Wahren Fred Mhalu Merlin L Robb Gunnel Biberfeld Eric Sandström Muhammad Bakari |
| author_facet | Patricia J Munseri Arne Kroidl Charlotta Nilsson Agricola Joachim Christof Geldmacher Philipp Mann Candida Moshiro Said Aboud Eligius Lyamuya Leonard Maboko Marco Missanga Bahati Kaluwa Sayoki Mfinanga Lilly Podola Asli Bauer Karina Godoy-Ramirez Mary Marovich Bernard Moss Michael Hoelscher Frances Gotch Wolfgang Stöhr Richard Stout Sheena McCormack Britta Wahren Fred Mhalu Merlin L Robb Gunnel Biberfeld Eric Sandström Muhammad Bakari |
| author_sort | Patricia J Munseri |
| collection | DOAJ |
| description | <h4>Background</h4>Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explores whether HIV-DNA priming can be simplified by reducing the number of DNA injections and administration of combined versus separated plasmid pools.<h4>Methods</h4>In this phase IIa, randomized trial, priming was performed using 5 injections of HIV-DNA, 1000 μg total dose, (3 Env and 2 Gag encoding plasmids) compared to two "simplified" regimens of 2 injections of HIV-DNA, 600 μg total dose, of Env- and Gag-encoding plasmid pools with each pool either administered separately or combined. HIV-DNA immunizations were given intradermally at weeks 0, 4, and 12. Boosting was performed intramuscularly with 108 pfu HIV-MVA at weeks 30 and 46.<h4>Results</h4>129 healthy Tanzanian participants were enrolled. There were no differences in adverse events between the groups. The proportion of IFN-γ ELISpot responders to Gag and/or Env peptides after the second HIV-MVA boost did not differ significantly between the groups primed with 2 injections of combined HIV-DNA pools, 2 injections with separated pools, and 5 injections with separated pools (90%, 97% and 97%). There were no significant differences in the magnitude of Gag and/or Env IFN-γ ELISpot responses, in CD4+ and CD8+ T cell responses measured as IFN-γ/IL-2 production by intracellular cytokine staining (ICS) or in response rates and median titers for binding antibodies to Env gp160 between study groups.<h4>Conclusions</h4>A simplified intradermal vaccination regimen with 2 injections of a total of 600 μg with combined HIV-DNA plasmids primed cellular responses as efficiently as the standard regimen of 5 injections of a total of 1000 μg with separated plasmid pools after boosting twice with HIV-MVA.<h4>Trial registration</h4>World Health Organization International Clinical Trials Registry Platform PACTR2010050002122368. |
| format | Article |
| id | doaj-art-e5e9b58917bb44f98a3a9654a78c5a2f |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e5e9b58917bb44f98a3a9654a78c5a2f2025-08-20T03:46:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e011962910.1371/journal.pone.0119629Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.Patricia J MunseriArne KroidlCharlotta NilssonAgricola JoachimChristof GeldmacherPhilipp MannCandida MoshiroSaid AboudEligius LyamuyaLeonard MabokoMarco MissangaBahati KaluwaSayoki MfinangaLilly PodolaAsli BauerKarina Godoy-RamirezMary MarovichBernard MossMichael HoelscherFrances GotchWolfgang StöhrRichard StoutSheena McCormackBritta WahrenFred MhaluMerlin L RobbGunnel BiberfeldEric SandströmMuhammad Bakari<h4>Background</h4>Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explores whether HIV-DNA priming can be simplified by reducing the number of DNA injections and administration of combined versus separated plasmid pools.<h4>Methods</h4>In this phase IIa, randomized trial, priming was performed using 5 injections of HIV-DNA, 1000 μg total dose, (3 Env and 2 Gag encoding plasmids) compared to two "simplified" regimens of 2 injections of HIV-DNA, 600 μg total dose, of Env- and Gag-encoding plasmid pools with each pool either administered separately or combined. HIV-DNA immunizations were given intradermally at weeks 0, 4, and 12. Boosting was performed intramuscularly with 108 pfu HIV-MVA at weeks 30 and 46.<h4>Results</h4>129 healthy Tanzanian participants were enrolled. There were no differences in adverse events between the groups. The proportion of IFN-γ ELISpot responders to Gag and/or Env peptides after the second HIV-MVA boost did not differ significantly between the groups primed with 2 injections of combined HIV-DNA pools, 2 injections with separated pools, and 5 injections with separated pools (90%, 97% and 97%). There were no significant differences in the magnitude of Gag and/or Env IFN-γ ELISpot responses, in CD4+ and CD8+ T cell responses measured as IFN-γ/IL-2 production by intracellular cytokine staining (ICS) or in response rates and median titers for binding antibodies to Env gp160 between study groups.<h4>Conclusions</h4>A simplified intradermal vaccination regimen with 2 injections of a total of 600 μg with combined HIV-DNA plasmids primed cellular responses as efficiently as the standard regimen of 5 injections of a total of 1000 μg with separated plasmid pools after boosting twice with HIV-MVA.<h4>Trial registration</h4>World Health Organization International Clinical Trials Registry Platform PACTR2010050002122368.https://doi.org/10.1371/journal.pone.0119629 |
| spellingShingle | Patricia J Munseri Arne Kroidl Charlotta Nilsson Agricola Joachim Christof Geldmacher Philipp Mann Candida Moshiro Said Aboud Eligius Lyamuya Leonard Maboko Marco Missanga Bahati Kaluwa Sayoki Mfinanga Lilly Podola Asli Bauer Karina Godoy-Ramirez Mary Marovich Bernard Moss Michael Hoelscher Frances Gotch Wolfgang Stöhr Richard Stout Sheena McCormack Britta Wahren Fred Mhalu Merlin L Robb Gunnel Biberfeld Eric Sandström Muhammad Bakari Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. PLoS ONE |
| title | Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. |
| title_full | Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. |
| title_fullStr | Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. |
| title_full_unstemmed | Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. |
| title_short | Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. |
| title_sort | priming with a simplified intradermal hiv 1 dna vaccine regimen followed by boosting with recombinant hiv 1 mva vaccine is safe and immunogenic a phase iia randomized clinical trial |
| url | https://doi.org/10.1371/journal.pone.0119629 |
| work_keys_str_mv | AT patriciajmunseri primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT arnekroidl primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT charlottanilsson primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT agricolajoachim primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT christofgeldmacher primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT philippmann primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT candidamoshiro primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT saidaboud primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT eligiuslyamuya primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT leonardmaboko primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT marcomissanga primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT bahatikaluwa primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT sayokimfinanga primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT lillypodola primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT aslibauer primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT karinagodoyramirez primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT marymarovich primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT bernardmoss primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT michaelhoelscher primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT francesgotch primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT wolfgangstohr primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT richardstout primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT sheenamccormack primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT brittawahren primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT fredmhalu primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT merlinlrobb primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT gunnelbiberfeld primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT ericsandstrom primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial AT muhammadbakari primingwithasimplifiedintradermalhiv1dnavaccineregimenfollowedbyboostingwithrecombinanthiv1mvavaccineissafeandimmunogenicaphaseiiarandomizedclinicaltrial |